iShares Core U.S. REIT ETF (USRT) NPORT-P iShares U.S. Medical Devices ETF (Jun 2024 report)

iShares

®

U.S.

Medical

Devices

ETF

Schedule

of

Investments

(unaudited)

June

30,

2024

(Percentages

shown

are

based

on

Net

Assets)

1

Schedule

of

Investments

Security

Shares

Value

a

Common

Stocks

Health

Care

Equipment

 — 

99

.8

%

Abbott

Laboratories

........................

7,905,571

$

821,467,883

Alphatec

Holdings,

Inc.

(a)

(b)

....................

670,912

7,011,030

Artivion,

Inc.

(a)

(b)

...........................

267,818

6,869,532

AtriCure,

Inc.

(a)

(b)

..........................

326,827

7,441,851

Axogen,

Inc.

(a)

............................

295,228

2,137,451

Axonics,

Inc.

(a)

............................

344,630

23,169,475

Baxter

International,

Inc.

.....................

3,442,307

115,145,169

Becton

Dickinson

&

Co.

.....................

988,163

230,943,575

Boston

Scientific

Corp.

(a)

.....................

3,400,438

261,867,730

CONMED

Corp.

...........................

208,064

14,422,996

Dexcom,

Inc.

(a)

...........................

1,972,870

223,684,001

Edwards

Lifesciences

Corp.

(a)

(b)

................

2,634,392

243,338,789

Enovis

Corp.

(a)

(b)

...........................

337,173

15,240,220

Envista

Holdings

Corp.

(a)

(b)

....................

1,160,939

19,306,416

GE

HealthCare

Technologies,

Inc.

..............

2,867,651

223,447,366

Glaukos

Corp.

(a)

...........................

340,249

40,268,469

Globus

Medical,

Inc.

,

Class

A

(a)

(b)

...............

760,823

52,108,767

Hologic,

Inc.

(a)

............................

1,576,502

117,055,274

IDEXX

Laboratories,

Inc.

(a)

(b)

..................

449,602

219,046,094

Inari

Medical,

Inc.

(a)

(b)

.......................

349,537

16,830,207

Inspire

Medical

Systems,

Inc.

(a)

(b)

...............

200,701

26,859,815

Insulet

Corp.

(a)

............................

473,132

95,478,038

Integer

Holdings

Corp.

(a)

(b)

....................

226,323

26,205,940

Integra

LifeSciences

Holdings

Corp.

(a)

(b)

...........

463,116

13,495,200

Intuitive

Surgical,

Inc.

(a)

(b)

.....................

1,611,926

717,065,281

iRhythm

Technologies,

Inc.

(a)

(b)

.................

210,120

22,617,317

LeMaitre

Vascular,

Inc.

......................

134,946

11,103,357

LivaNova

PLC

(a)

...........................

365,810

20,053,704

Masimo

Corp.

(a)

...........................

301,227

37,936,528

Medtronic

PLC

...........................

2,811,879

221,322,996

Nevro

Corp.

(a)

(b)

...........................

248,108

2,089,069

Novocure

Ltd.

(a)

...........................

661,509

11,331,649

Omnicell,

Inc.

(a)

...........................

310,215

8,397,520

Orthofix

Medical,

Inc.

(a)

......................

253,511

3,361,556

Paragon

28,

Inc.

(a)

(b)

........................

243,336

1,664,418

Penumbra,

Inc.

(a)

(b)

.........................

261,870

47,128,744

Security

Shares

Value

a

Health

Care

Equipment

(continued)

PROCEPT

BioRobotics

Corp.

(a)

(b)

...............

302,226

$

18,462,986

QuidelOrtho

Corp.

(a)

(b)

.......................

334,786

11,121,591

ResMed,

Inc.

............................

992,386

189,962,528

Senseonics

Holdings,

Inc.

(a)

...................

143,161

57,121

SI-BONE,

Inc.

(a)

(b)

..........................

253,290

3,275,040

Silk

Road

Medical,

Inc.

(a)

.....................

266,449

7,204,781

STERIS

PLC

.............................

667,512

146,545,584

Stryker

Corp.

............................

1,540,759

524,243,250

Surmodics,

Inc.

(a)

..........................

96,324

4,049,461

Tandem

Diabetes

Care,

Inc.

(a)

(b)

................

436,314

17,579,091

Teleflex,

Inc.

.............................

318,192

66,925,323

TransMedics

Group,

Inc.

(a)

(b)

...................

222,492

33,511,745

Treace

Medical

Concepts,

Inc.

(a)

(b)

...............

293,221

1,949,920

Varex

Imaging

Corp.

(a)

......................

276,291

4,069,766

Zimmer

Biomet

Holdings,

Inc.

.................

1,389,724

150,826,746

a

Total

Long-Term Investments

— 99.8%

(Cost:

$

5,298,558,278

)

...............................

5,106,698,360

a

Short-Term

Securities

Money

Market

Funds

 — 

2

.2

%

BlackRock

Cash

Funds:

Institutional,

SL

Agency

Shares

,

5.48

%

(c)

(d)

(e)

............................

106,246,309

106,278,182

BlackRock

Cash

Funds:

Treasury,

SL

Agency

Shares

,

5.28

%

(c)

(d)

.............................

7,522,031

7,522,031

a

Total

Short-Term

Securities — 2.2%

(Cost:

$

113,767,002

)

................................

113,800,213

Total

Investments

—

102.0%

(Cost:

$

5,412,325,280

)

...............................

5,220,498,573

Liabilities

in

Excess

of

Other

Assets

—

(

2

.0

)

%

...............

(

103,005,526

)

Net

Assets

—

100.0%

.................................

$

5,117,493,047

(a)

Non-income

producing

security.

(b)

All

or

a

portion

of

this

security

is

on

loan.

(c)

Affiliate

of

the

Fund.

(d)

Annualized

7-day

yield

as

of

period

end.

(e)

All

or

a

portion

of

this

security

was

purchased

with

the

cash

collateral

from

loaned

securities.

Affiliates

Investments

in

issuers

considered

to

be

affiliate(s)

of

the

Fund

during

the

period

ended

June

30,

2024

for

purposes

of

Section

2(a)(3)

of

the

Investment

Company

Act

of

1940,

as

amended,

were

as

follows:

Affiliated

Issuer

Value

at

03/31/24

Purchases

at

Cost

Proceeds

from

Sale

Net

Realized

Gain

(Loss)

Change

in

Unrealized

Appreciation

(Depreciation)

Value

at

06/30/24

  Shares

Held

at

06/30/24

Income

  Capital

Gain

Distributions

from

Underlying

Funds

BlackRock

Cash

Funds:

Institutional,

SL

Agency

Shares

$

119,537,217

‌

$

—

‌

$

(

13,255,080

)

(a)

$

1,134

‌

$

(

5,089

)

$

106,278,182

‌

106,246,309

‌

$

61,956

(b)

$

—

‌

BlackRock

Cash

Funds:

Treasury,

SL

Agency

Shares

......

6,174,241

‌

1,347,790

(a)

—

‌

—

‌

—

‌

7,522,031

‌

7,522,031

‌

102,782

‌

—

‌

$

1,134

‌

$

(

5,089

)

$

113,800,213

‌

$

164,738

‌

$

—

‌

Schedule

of

Investments

(unaudited)

(continued)

June

30,

2024

iShares

®

U.S.

Medical

Devices

ETF

2

Derivative

Financial

Instruments

Outstanding

as

of

Period

End

Fair

Value

Hierarchy

as

of

Period

End

Various

inputs

are

used

in

determining

the

fair

value

of

financial

instruments.

These

inputs

to

valuation

techniques

are

categorized

into

a

fair

value

hierarchy

consisting

of

three

broad

levels

for

financial

reporting

purposes

as

follows:

Level

1

–

Unadjusted

price

quotations

in

active

markets/exchanges

for

identical

assets

or

liabilities

that

the

Fund

has

the

ability

to

access;

Level

2

–

Other

observable

inputs

(including,

but

not

limited

to,

quoted

prices

for

similar

assets

or

liabilities

in

markets

that

are

active,

quoted

prices

for

identical

or

similar

assets

or

liabilities

in

markets

that

are

not

active,

inputs

other

than

quoted

prices

that

are

observable

for

the

assets

or

liabilities

(such

as

interest

rates,

yield

curves,

volatilities,

prepayment

speeds,

loss

severities,

credit

risks

and

default

rates)

or

other

market–corroborated

inputs);

and

Level

3

–

Unobservable

inputs

based

on

the

best

information

available

in

the

circumstances,

to

the

extent

observable

inputs

are

not

available

(including

the

Valuation

Committee’s

assumptions

used

in

determining

the

fair

value

of

financial

instruments).

The

hierarchy

gives

the

highest

priority

to

unadjusted

quoted

prices

in

active

markets

for

identical

assets

or

liabilities

(Level

1

measurements)

and

the

lowest

priority

to

unobservable

inputs

(Level

3

measurements).

Accordingly,

the

degree

of

judgment

exercised

in

determining

fair

value

is

greatest

for

instruments

categorized

in

Level

3.

The

inputs

used

to

measure

fair

value

may

fall

into

different

levels

of

the

fair

value

hierarchy.

In

such

cases,

for

disclosure

purposes,

the

fair

value

hierarchy

classification

is

determined

based

on

the

lowest

level

input

that

is

significant

to

the

fair

value

measurement

in

its

entirety.

Investments

classified

within

Level

3

have

significant

unobservable

inputs

used

by

the

Valuation

Committee

in

determining

the

price

for

Fair

Valued

Investments.

Level

3

investments

include

equity

or

debt

issued

by

privately

held

companies

or

funds.

There

may

not

be

a

secondary

market,

and/or

there

are

a

limited

number

of

investors.

The

categorization

of

a

value

determined

for

financial

instruments

is

based

on

the

pricing

transparency

of

the

financial

instruments

and

is

not

necessarily

an

indication

of

the

risks

associated

with

investing

in

those

securities.

For

information

about

the

Fund’s

policy

regarding

valuation

of

financial

instruments,

refer

to

its

most

recent

financial

statements.

The

following

table

summarizes

the

Fund’s

financial

instruments

categorized

in

the

fair

value

hierarchy.

The

breakdown

of

the

Fund’s

financial

instruments

into

major

categories

is

disclosed

in

the

Schedule

of

Investments

above. 

(a)

Represents

net

amount

purchased

(sold).

(b)

All

or

a

portion

represents

securities

lending

income

earned

from

the

reinvestment

of

cash

collateral

from

loaned

securities,

net

of

fees

and

collateral

investment

expenses,

and

other

payments

to

and

from

borrowers

of

securities.

Futures

Contracts

Description

Number

of

Contracts

Expiration

Date

Notional

Amount

(000)

Value/

Unrealized

Appreciation

(Depreciation)

Long

Contracts

E-Mini

Health

Care

Select

Sector

Index

......................................................

52

09/20/24

$

7,745

$

(

9,137

)

E-Mini

Technology

Select

Sector

Index

......................................................

11

09/20/24

2,539

(

7,357

)

$

(

16,494

)

Level

1

Level

2

Level

3

Total

Assets

Investments

Long-Term

Investments

Common

Stocks

.........................................

$

5,106,698,360

‌

$

—

‌

$

—

‌

$

5,106,698,360

‌

Short-Term

Securities

Money

Market

Funds

......................................

113,800,213

‌

—

‌

—

‌

113,800,213

‌

$

5,220,498,573

‌

$

—

‌

$

—

‌

$

5,220,498,573

‌

Derivative

Financial

Instruments

(a)

Liabilities

Equity

Contracts

...........................................

$

(

16,494

)

$

—

‌

$

—

‌

$

(

16,494

)

a

(a)

Derivative

financial

instruments

are

futures

contracts.

Futures

contracts

are

valued

at

the

unrealized

appreciation

(depreciation)

on

the

instrument.